Extracellular vesicles-derived CXCL4 is a candidate serum tumor biomarker for colorectal cancer.

Abstract

Extracellular vesicles (EVs) were promising circulating biomarkers for multiple diseases, but whether serum EVs-derived proteins could be used as a reliable tumor biomarker for colorectal cancer (CRC) remained inconclusive. In this study, we identified CXCL4 by a 4D data-independent acquisition-based quantitative proteomics assay of serum EVs-derived proteins in 40 individuals and subsequently analyzed serum EVs-derived CXCL4 levels by ELISA in 2 cohorts of 749 individuals. The results revealed that EVs-derived CXCL4 levels were dramatically elevated in CRC patients than in benign colorectal polyp patients or healthy controls (HC). Furthermore, receiver operating characteristic curves revealed that EVs-derived CXCL4 exhibited superior diagnostic performance with area under the curve of 0.948 in the training cohort. Additionally, CXCL4 could effectively distinguish CRC in stage I/II from HC. Notably, CRC patients with high levels of EVs-derived CXCL4 have shorter 2-year progression-free survival than those with low levels. Overall, our findings demonstrated that serum EVs-derived CXCL4 was a candidate diagnostic and prognostic biomarker for CRC.

• Authors: Jinye Xie, Shan Xing, Hongbo Jiang, Jiaju Zhang, Daxiao Li, Shiqiong Niu, Zhijian Huang, Haofan Yin
• Journal: iScience (iScience) Vol. 27 Issue 4 Pg. 109612 (Apr 19 2024) ISSN: 2589-0042 [Electronic] United States
• PMID: 38632995 (Publication Type: Journal Article)
• Copyright: © 2024 The Authors.